Grace Therapeutics, Inc. GRCE
Set alert
1.94 USD 0.00 0.00%
At close · Oct 30
1.94 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
1.87 Day range 1.98
1.81 52-week range 5.13
- YTD
- -43.93%
- 1 year
- -39.18%
- Open
- 1.95
- Prev close
- 1.94
- Mkt cap
- 40.81M
- Vol
- 85.94K
- Avg vol
- 139.87K
- EPS
- -1.17
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.87
- High
- 1.98
- Forward P/E
- -2.90
- Beta
- 1.51
- Short ratio
- 3.25
- Inst. own
- 21.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 10, 2025
- 50-d avg
- 3.44
- 200-d avg
- 3.04
- 1y target
- 10.44
Financial health
Altman Z-Score
6.00 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 5
Valuation
P/E -9.9×
FY 2017 5y median -1.6× FY 2026
P/S 0.0×
FY 2017 5y median 0.0× FY 2026
P/B 1.2×
FY 2017 5y median 0.4× FY 2026
P/FCF -8.6×
FY 2017 5y median -1.8× FY 2026
EV/EBITDA -5.4×
FY 2017 5y median -0.2× FY 2026
EV/Sales 0.0×
FY 2017 5y median 0.0× FY 2026
FCF Yield -11.6%
FY 2017 5y median -54.1% FY 2026
Profitability
Gross Margin 0.0%
FY 2017 5y median 0.0% FY 2026
Operating Margin 0.0%
FY 2017 5y median 0.0% FY 2026
Net Margin 0.0%
FY 2017 5y median 0.0% FY 2026
ROE -12.2%
FY 2017 5y median -20.5% FY 2026
ROIC -14.1%
FY 2017 5y median -21.3% FY 2026
ROA -11.7%
FY 2017 5y median -18.9% FY 2026
Growth (YoY)
Revenue 0.0%
FY 2017 FY 2026
Operating Income 53.4%
FY 2017 FY 2026
EPS (diluted) 58.4%
FY 2017 FY 2026
Free Cash Flow 40.5%
FY 2017 FY 2026
Financial Health
Current Ratio 8.1×
FY 2017 5y median 11.8× FY 2026
Quick Ratio 8.1×
FY 2017 5y median 11.8× FY 2026
Debt / Equity 0.0×
FY 2017 5y median 0.0× FY 2026
Net Debt / EBITDA 1.5×
FY 2017 5y median 1.5× FY 2026
Interest Coverage 0.0×
FY 2017 5y median 0.0× FY 2026
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2026
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2026
Annual · latest fiscal year ends 2026-03-31